• What’s spooking investors about Xero shares?

    Two passengers freak out in a plane cabin.

    12 months ago, Xero Ltd (ASX: XRO) shares were flying high, reaching a record high of $196.52. Fast forward a year, and the picture looks dramatically different.

    At the time of writing, the accounting software company’s shares change hands for around $65.00, a 7-year low. That leaves the stock down more than 40% since the start of 2026 and roughly 66% lower than this time last year.

    It’s been a brutal period for shareholders.

    So what on earth is happening with this former ASX tech darling?

    Why are Xero shares under pressure?

    The latest weakness appears to be part of the broader sell-off that has swept through growth stocks.

    Investors have become far less willing to pay premium valuations for technology companies, particularly those whose investment appeal depends heavily on future growth. As sentiment towards the sector has deteriorated, Xero shares have come under fire.

    The market simply isn’t valuing software businesses the way it did during the boom years.

    That doesn’t necessarily mean there’s anything fundamentally wrong with the company.

    Business is still performing

    While the price of Xero shares has collapsed, Xero’s operating performance tells a very different story.

    Revenue surged 31% to NZ$2.75 billion in the most recent financial year, highlighting continued strong demand for its accounting software platform.

    Adjusted EBITDA increased 18% to NZ$757.4 million, while free cash flow reached NZ$554 million.

    Perhaps most importantly, annualised recurring revenue jumped 37%.

    That’s a key metric for software companies because recurring subscription income provides visibility and predictability. Investors typically place a high value on businesses that can generate growing streams of recurring revenue.

    In other words, the business continues to grow even as the share price struggles.

    US opportunity remains enormous

    One reason some investors remain optimistic about Xero shares is the company’s growing traction in the US.

    For years, the US small-business market has been viewed as the company’s biggest long-term opportunity. Success there could significantly expand Xero’s addressable market and growth runway.

    Encouragingly, organic growth in the US reportedly accelerated to 30%.

    That’s an important milestone. If Xero can establish itself as a meaningful player in the world’s largest accounting software market, the long-term growth potential becomes far more compelling.

    Management’s outlook also suggests growth remains firmly on the agenda. The company is targeting roughly 34% revenue growth in FY27 and expects adjusted EBITDA to land between NZ$860 million and NZ$920 million.

    Those numbers hardly describe a business running out of steam.

    What next for Xero shares?

    Despite the strong operating performance, risks remain.

    Investors are still waiting to see how the company’s Melio acquisition progresses, while broader market sentiment towards software stocks remains fragile.

    That’s helping explain why Xero shares continue to trade well below previous highs.

    Even so, some analysts see value emerging. Shaw and Partners believes the stock offers approximately 25% upside from current levels.

    For now, the market appears torn between two competing narratives: a rapidly growing software business and a growth stock sector that remains deeply out of favour. Which story wins may determine where Xero shares head next.

    The post What’s spooking investors about Xero shares? appeared first on The Motley Fool Australia.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now…

    * Returns as of 16 June 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • These ASX 200 shares are down 40% to 65% and could be bargain buys

    Man with a hand on his head looks at a red stock market chart showing a falling share price.

    Some of the ASX 200’s highest-quality shares have been hit hard over the past 12 months.

    While this is disappointing, for investors with a long-term mindset, large falls in strong businesses can create buying opportunities.

    This is especially true when the market becomes focused on short-term concerns while the company’s long-term position remains attractive.

    Here are three ASX 200 shares that are down heavily and could be bargain buys for patient investors.

    Cochlear Ltd (ASX: COH)

    Cochlear has been one of the biggest underperforming shares in the ASX 200 over the past 12 months.

    Its shares are down approximately 62% over this period, leaving the hearing implant company well out of favour with investors.

    That is a major move for a business with a long record of innovation, global leadership, and life-changing products.

    Cochlear’s devices help people with significant hearing loss reconnect with speech, sound, and daily communication. That gives the company a role that goes well beyond consumer electronics or discretionary healthcare.

    The business operates in a specialised market where clinical trust, product reliability, surgeon relationships, and long-term patient support all matter.

    Those advantages take years to build.

    The recent share price weakness reflects disappointment over its recent performance. However, the long-term need for hearing solutions should continue to grow as populations age and access to treatment improves.

    If Cochlear can restore confidence in its earnings trajectory, the selloff could prove to be a major opportunity for buy and hold investors.

    REA Group Ltd (ASX: REA)

    REA has also been sold down heavily.

    Its shares are down approximately 40% over the past 12 months amid concerns about higher interest rates and proposed changes to negative gearing.

    These issues have weighed on investor sentiment because REA is closely connected to the housing market. If property activity slows, listing volumes and advertising demand can come under pressure.

    But the long-term investment case remains compelling.

    REA owns realestate.com.au, one of Australia’s most important property platforms. Buyers go there because the listings are there, agents list there because the audience is there, and vendors want access to the largest possible pool of potential buyers.

    That loop gives REA a powerful position in the property ecosystem.

    Housing markets move through cycles, and policy changes can affect confidence. But Australians remain deeply engaged with property, and digital marketplaces continue to play a central role in how homes are bought and sold.

    A 40% fall may have created an opportunity to buy one of the ASX’s best digital businesses at a far more attractive price.

    Xero Ltd (ASX: XRO)

    Xero has suffered the sharpest fall of the three ASX 200 shares.

    The cloud accounting software company’s shares are down approximately 65% over the past 12 months.

    The broader tech selloff has hurt sentiment, and investors have also been weighing concerns about artificial intelligence disruption across software markets.

    That has created a difficult backdrop for Xero.

    However, the company remains deeply embedded in the financial workflows of small businesses, accountants, and bookkeepers.

    Its platform helps users manage invoicing, payroll, bank feeds, reporting, compliance, payments, and adviser relationships. Once a business has built its financial processes around Xero, switching can become inconvenient and disruptive.

    Artificial intelligence may also become a useful tool inside the platform over time, helping automate tasks and improve the value customers receive.

    The share price fall shows how much expectations have reset. But if Xero keeps expanding internationally, adds more services, and uses technology to deepen its platform, the current weakness could prove to be an attractive entry point into one of the ASX’s strongest software businesses.

    The post These ASX 200 shares are down 40% to 65% and could be bargain buys appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Cochlear right now?

    Before you buy Cochlear shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Cochlear wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 16 June 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor James Mickleboro has positions in Cochlear, REA Group, and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear and Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • Bell Potter tips 129% upside for this ASX materials stock

    Cheerful businessman with a mining hat on the table sitting back with his arms behind his head while looking at his laptop's screen.

    The team at Bell Potter have been consistently bullish on ASX materials stock WA1 Resources Ltd (ASX: WA1) this year. 

    WA1 listed on the ASX in February 2022. Since then, it has focused on an aggressive drill-out program at West Arunta, specifically targeting the Luni carbonatite structure. 

    Niobium is a niche commodity, primarily micro-alloyed into structural steel to improve strength and reduce weight in applications.

    In the last 12 months, this ASX materials stock has been relatively flat.

    However a key announcement has led to a strong upgrade from the team at Bell Potter who now see this ASX materials stock as one that could double in the next 12 months. 

    What happened?

    WA1 has completed larger-scale processing tests on ore from its Luni niobium project. 

    The tests showed the company can successfully concentrate the niobium into a high-grade product using a relatively simple flotation process and ordinary site water.

    For investors, this is a big positive as one of the biggest risks for any mining project is whether the ore can actually be processed economically.

    These results show that:

    • The processing method appears to work consistently across different parts of the deposit.
    • The quality of the concentrate produced is high enough to be commercially attractive.
    • The project’s future processing plant design is becoming more certain.

    In mining terms, this “de-risks” the project because investors now have more confidence that the ore can be turned into a saleable product.

    Standout results

    The best area of the deposit (Composite A), which is expected to be mined first, delivered:

    • 46% niobium concentrate grade
    • 67% recovery rate.

    Recovery rate means 67% of the niobium in the ore was successfully captured during processing.

    This was better than previous test results and suggests the project could be more profitable than originally expected.

    Because recoveries were stronger than expected, Bell Potter increased its assumption for how much niobium WA1 can extract from the ore.

    Big upgrade for ASX materials stock

    As a result, Bell Potter has upgraded its price target on this ASX materials stock to $27.20 (previously $24.40). 

    This is significant because this ASX materials stock currently trades for around $12.50 per share. 

    The new target from Bell Potter indicates an upside potential of 129%. 

    The testwork confirms a two-stage flotation regime can produce high-quality niobium concentrates with commercially relevant recoveries across the deposit, using raw site water.

    The broker has retained its speculative buy recommendation. 

    The post Bell Potter tips 129% upside for this ASX materials stock appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Wa1 Resources right now?

    Before you buy Wa1 Resources shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Wa1 Resources wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 16 June 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.